{"transactions":[{"id":11895,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10993,"kind":"person","name":"Purdue David Ryan","position":1,"cik":"0002057696","reported_name":"Purdue David Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-11T17:00:20.000Z","date":"2026-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":2108,"price":232.08,"value":489224.64,"ownership":{"direct":true},"balance_after":8468,"source":{"system":"sec-edgar","filing":"0002057696-26-000010","document":"form4a-03112026_050317.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2057696/000205769626000010/form4a-03112026_050317.xml","form_type":"4/A","original_submission_date":"2026-03-03"}},{"id":11988,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10993,"kind":"person","name":"Purdue David Ryan","position":1,"cik":"0002057696","reported_name":"Purdue David Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-06T17:05:44.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":5230,"price":233.56,"value":1221518.8,"ownership":{"direct":true},"balance_after":2654,"source":{"system":"sec-edgar","filing":"0002057696-26-000008","document":"form4-03062026_100340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2057696/000205769626000008/form4-03062026_100340.xml","form_type":"4"}},{"id":12308,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10993,"kind":"person","name":"Purdue David Ryan","position":1,"cik":"0002057696","reported_name":"Purdue David Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-03T18:10:10.000Z","date":"2026-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":2692,"price":232.08,"value":624759.36,"ownership":{"direct":true},"balance_after":7884,"source":{"system":"sec-edgar","filing":"0002057696-26-000004","document":"form4-03032026_060303.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2057696/000205769626000004/form4-03032026_060303.xml","form_type":"4"}},{"id":13204,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10993,"kind":"person","name":"Purdue David Ryan","position":1,"cik":"0002057696","reported_name":"Purdue David Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Controller"}}],"security":"Option (Right to buy)","published_at":"2026-02-20T18:35:27.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":4875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 1,625 on February 18, 2027, 1,625 on February 18, 2028, and 1,625 on February 18, 2029."}],"balance_after":4875,"derivative":{"exercise_price":230.04,"expiration_date":"2036-02-17","underlying":"Common Stock","underlying_shares":4875},"source":{"system":"sec-edgar","filing":"0002057696-26-000002","document":"form4-02202026_060215.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2057696/000205769626000002/form4-02202026_060215.xml","form_type":"4"}},{"id":13203,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10993,"kind":"person","name":"Purdue David Ryan","position":1,"cik":"0002057696","reported_name":"Purdue David Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T18:35:27.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":1384,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":10576,"source":{"system":"sec-edgar","filing":"0002057696-26-000002","document":"form4-02202026_060215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2057696/000205769626000002/form4-02202026_060215.xml","form_type":"4"}},{"id":13202,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10993,"kind":"person","name":"Purdue David Ryan","position":1,"cik":"0002057696","reported_name":"Purdue David Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T18:35:27.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":1292,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":9192,"source":{"system":"sec-edgar","filing":"0002057696-26-000002","document":"form4-02202026_060215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2057696/000205769626000002/form4-02202026_060215.xml","form_type":"4"}},{"id":13201,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10993,"kind":"person","name":"Purdue David Ryan","position":1,"cik":"0002057696","reported_name":"Purdue David Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T18:35:27.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":7900,"source":{"system":"sec-edgar","filing":"0002057696-26-000002","document":"form4-02202026_060215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2057696/000205769626000002/form4-02202026_060215.xml","form_type":"4"}},{"id":13200,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10993,"kind":"person","name":"Purdue David Ryan","position":1,"cik":"0002057696","reported_name":"Purdue David Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T18:35:27.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":2505,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":7010,"source":{"system":"sec-edgar","filing":"0002057696-26-000002","document":"form4-02202026_060215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2057696/000205769626000002/form4-02202026_060215.xml","form_type":"4"}}]}